pharma

The Future of Thought Leaders in Healthcare

Industry Insights from Paul Meade, M.Sc, MPH For decades, the pharmaceutical industry has had a good working relationship with the medical profession. Of course, pharmaceutical companies have always been dependent on physicians writing prescriptions for their products, and for pharmacists filling these prescriptions, so ultimately the patients could return to health. This has been a …

The Future of Thought Leaders in Healthcare Read More »

Reflections on SMi Knowledge Leader Conference

Neil Mellor, business development consultant at Thought Leader Select, and Paul Meade, the company’s president and founder, attended SMi’s KOL: Knowledge Leader Partnerships conference on September 29 and 30 in London.  Neil sat down with the Thought Leader Select Blog to discuss his takeaways from the conference. TLS Blog:  Neil, how was the conference in …

Reflections on SMi Knowledge Leader Conference Read More »

Thought Leader Select Names Castle to Lead Marketing, Client Relations

FOR IMMEDIATE RELEASE MARCH 30, 2010 (CHAPEL HILL, NC)—Thought Leader Select, a North Carolina firm dedicated to better engagement and more sophisticated deployment of key opinion leaders for the pharmaceutical and biotechnology industries, announces the hiring of Brian Castle as director of global marketing and client relations. Mr. Castle, a native of Jackson, MS, spent …

Thought Leader Select Names Castle to Lead Marketing, Client Relations Read More »

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Three

Key Opinion Leaders Help to Foster Robust, Viable Pharmaceutical and Biotechnology Pipelines Imagine a world where pharmaceutical and biotechnology companies developed therapies without input from KOLs at various stages of product discovery and development. The results would be far fewer treatments available, greater risks for unwanted side effects and potentially, a larger number of unnecessary …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Three Read More »

PharmExec's 2010 Forecast Reflected in Thought Leader Select's Current Projects

While 2010 continues to be a challenging year for the pharmaceutical industry as a whole, certain targeted areas of development continue to gain attention from the industry. In PharmExec’s 2010 forecast,Alexandra Kibble predicted continued focus on the following therapeutic areas:  cardiovascular, oncology, and anti-infectives.  Kibble also predicted a rise in pipeline development of treatments for …

PharmExec's 2010 Forecast Reflected in Thought Leader Select's Current Projects Read More »

CME Demanding Greater Compliance through Faculty Selection Criteria Consistency

With heightened scrutiny on the objectivity of Continuing Medical Education meetings in recent years, pharmaceutical companies have placed more emphasis on understanding skills and experiences of physician Thought Leaders who may serve as CME faculty. In addition to publishing grant databases which outline monies paid to speakers, CME faculty and other advisors, leading companies are …

CME Demanding Greater Compliance through Faculty Selection Criteria Consistency Read More »

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part Two

KOLs Provide the “Voice of the Patient” for Life-changing Discoveries According to the Pharmaceutical Research and Manufacturers of America (PhRMA—(http://www.phrma.org/), “Only one of every 10,000 potential medicines investigated by America’s research-based pharmaceutical companies makes it through the research and development pipeline and is approved for patient use by the United States Food and Drug Administration.” …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part Two Read More »